579000

Tamoxifen Citrate

≥99% (HPLC), Estrogen receptor modulator, powder

• Synonyma: Tamoxifen Citrate, Estrogen Receptor Signaling Regulator I
• Empirický vzorec (Hillův zápis): C₂₆H₂₉NO · xC₆H₈O₇
• Číslo CAS: 54965-24-1
• Molekulová hmotnost: 371.51 (salt-free basis)
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD00058321
• eCl@ss: 32160701
• Assay: ≥99% (HPLC)
• Form: powder
• Storage condition: OK to freeze

Vlastnosti

• Název produktu: Tamoxifen Citrate, Tamoxifen is a potent synthetic anti-estrogenic agent.
• description: Merck USA index - 14, 9048
• Quality Segment: 100
• assay: ≥99% (HPLC)
• form: powder
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze
• color: white to off-white
• solubility: ethanol: 5 mg/mL, methanol: 5 mg/mL, water: sparingly soluble
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: N(CCOc1ccc(cc1)\C(=C(\CC)/c3ccccc3)\c2ccccc2)(C)C.[O-]C(=O)C(O)(CC(=O)[O-])CC(=O)[O-].[H+].[H+].[H+]
• InChI: 1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
• InChI key: FQZYTYWMLGAPFJ-OQKDUQJOSA-N

Popis

General description

A potent synthetic anti-estrogen. A cell-permeable and reversible inhibitor of protein kinase C (IC₅₀ = 10 µM). Induces apoptosis in human malignant glioma cell lines.

A potent synthetic anti-estrogenic agent. A cell-permeable and reversible inhibitor of protein kinase C (IC₅₀ = 10 µM). Induces apoptosis in human malignant glioma cell lines and inhibits prostate cancer cell growth by induction of p21 protein.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
PKC

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 10 µM against protein kinase C

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Rohlff, C., et al. 1998. Prostate 37, 51.
Couldwell, W.J., et al. 1994. FEBS Lett.345, 43.
Baltuch, G.H., et al. 1993. Neurosurgery33, 495.
Powis, G. 1991. Trends Pharmacol. Sci.12, 188.
Issandou, M., et al. 1990. Cancer Res.50, 5845.
O’Brian, C.A., et al. 1985. Cancer Res.45, 2462.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

Bezpečnostní informace

• Piktogramy: GHS08,GHS07,GHS09
• Výstražné slovo: Danger
• Kódy nebezpečí: H302,H350,H360D,H410
• Bezpečnostní pokyny: P202 - P264 - P273 - P280 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B
• Skladovací třída: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Bod vzplanutí (°F): Not applicable
• Bod vzplanutí (°C): Not applicable